Skip to main content

Advertisement

Table 2 Cardiovascular safety markers, part I

From: Safety of TeaCrine®, a non-habituating, naturally-occurring purine alkaloid over eight weeks of continuous use

Variable T1 T2 T3 Time*group Time*group*gender
SBP (mm Hg)
 PLA 117 ± 15 116 ± 12 115 ± 13 Time p = 0.45 G*T*Ge p = 0.73
 LD 116 ± 9 115 ± 8 116 ± 6 G*T p = 0.12
 HD 118 ± 15 124 ± 12 122 ± 13
DBP (mm Hg)
 PLA 69 ± 9 68 ± 9 68 ± 9 Time p = 0.58 G*T*Ge p = 0.89
 LD 70 ± 7 67 ± 8 71 ± 8 G*T p = 0.53
 HD 70 ± 8 68 ± 8 73 ± 8
Heart rate (beats/min)
 PLA 60 ± 10 64 ± 8 63 ± 10 Time p= 0.032 G*T*Ge p = 0.85
 LD 60 ± 15 59 ± 10a 63 ± 12a G*T p = 0.35
 HD 59 ± 12 63 ± 10 64 ± 13
Vent Rate (breath/min)
 PLA 60 ± 9 61 ± 10 62 ± 8 Time p = 0.43 G*T*Ge p = 0.67
 LD 57 ± 13 59 ± 11 60 ± 13 G*T p = 0.10
 HD 63 ± 12 59 ± 11 61 ± 11
  1. Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
  2. Superscript letters, different letters are significantly different at a given time point (p < 0.05). Items in bold indicate a significant effect (p < 0.05) was observed